Tamosin Combo 6 mg/0,4 mg tablete s prilagođenim oslobađanjem
| Name | Tamosin Combo 6 mg/0,4 mg tablete s prilagođenim oslobađanjem |
|---|---|
| Marketing Authorisation Number | HR-H-742539300 |
| Active Substance | solifenacinsukcinat tamsulozinklorid |
| Composition | jedna tableta sadrži sloj sa 6 mg solifenacinsukcinata što odgovara 4,5 mg slobodne baze solifenacina i sloj sa 0,4 mg tamsulozinklorida što odgovara 0,37 mg slobodne baze tamsulozina |
| Pharmaceutical Form | tableta s prilagođenim oslobađanjem |
| Manufacturer | Belupo lijekovi i kozmetika d.d., Koprivnica, Hrvatska |
| Marketing Authorisation Holder | Belupo lijekovi i kozmetika d.d., Ulica Danica 5, Koprivnica, Hrvatska |
| Marketing Authorisation Date | 13.07.2022 |
| MA Period of Validity | 13.07.2027 |
| Classification Number | UP/I-530-09/21-01/167 |
| Registration Number | 381-12-01/154-22-06 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product on medical prescription for renewable delivery |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | G04CA53 |
| Marketing status | Marketed |
| Shortage status | No shortage |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
